MEDIVIR AB – INTERIM REPORT JANUARY – MARCH 2022

Momentum in several areas, not least the development of our cutting-edge project fostroxacitabine bralpamide January – MarchFinancial summary for the quarter · Net turnover amounted to SEK 0.5 (9.9) million. · The loss before interest, tax, depreciation and amortization (EBITDA) amounted to SEK -31.4 (-7.2) million. Basic and diluted earnings per share amounted to SEK -0.59 (-0.18) and SEK -0.59 (-0.18) respectively. · Cash flow from operating activities amounted to SEK -39.9 (-1.5) million. · Cash and cash equivalents at the end of the period amounted to SEK 180.8 (269.3)